While scientists have struggled for decades to produce an effective malaria vaccine, Rockville-based biotech company Sanaria is encouraged enough by clinical trials that it hopes to have its malaria vaccine on the market in three to five years, The Gazette reports.
The results of a Phase I clinical trial of the vaccine—published Thursday in the online issue of Science magazine—show that the vaccine provided complete protection against malaria in subjects who were exposed to malaria parasites, according to a news release from Sanaria.
{iframe}http://rockville.patch.com/groups/business-news/p/report-rockville-biotechs-malaria-vaccine-could-hit-market-soon{/iframe}